Catalog No.
Product Name
Application
Product Information
Citations
-
PROTAC BCL6 Degrader
PROTAC BCL6 Degrader-3 is a selective degrader targeting the BCL6 protein through the proteolysis-targeting chimera (PROTAC) approach. This compound mediates the ubiquitination and subsequent degradation of BCL6, facilitating the modulation of pathways associated with cancer and autoimmune diseases. It serves as a valuable tool for researchers exploring therapeutic strategies aimed at BCL6 inhibition and the underlying mechanisms of related diseases. -
BCL6 Inhibitor
CCT374705 is a potent BCL6 inhibitor with an IC50 value of 4.8 nM, demonstrating significant antiproliferative effects in vitro. This compound effectively inhibits tumor growth in lymphoma xenograft mouse models, making it a valuable reagent for investigating BCL6-related pathways in cancer research and potential therapeutic applications. -
EWSR1::FLI1 Binder
EB-TCIP is an EWSR1::FLI1 binder that operates by forming a ternary complex with the tagged fusion protein BCL6 and FKBP12F36V. This compound specifically recruits the EWSR1::FLI1 fusion to BCL6-associated DNA regions, leading to chromatin remodeling and the relocalization of transcriptional factors. As a result, EB-TCIP activates the expression of previously repressed BCL6 target genes. It serves as a valuable tool in the exploration of innovative epigenetic therapies for Ewing sarcoma. -
BCL6 Inhibitor
BCL6-IN-6 is a selective inhibitor targeting the transcriptional repressor B-cell lymphoma 6 (BCL6). It effectively disrupts the interaction between BCL6 and its corepressors, leading to the reactivation of BCL6 target genes in a dose-dependent manner. This compound is particularly relevant for studies focusing on diffuse large B-cell lymphoma (DLBCL) and related oncogenic pathways. -
BCL6 Inhibitor
GSK137 is a potent and selective inhibitor of B-cell lymphoma 6 (BCL6), acting primarily by disrupting the interaction between BCL6 and corepressors such as SMRT. This mechanism results in a reduction of germinal center B cells, making GSK137 a valuable tool for investigating autoimmune diseases, including systemic lupus erythematosus (SLE), and B-cell malignancies, such as diffuse large B-cell lymphoma. Its oral bioactivity aids in the exploration of therapeutic strategies targeting these conditions. -
BCL6 Inhibitor
BCL6-IN-11 is a potent BCL6 inhibitor that disrupts the interaction between BCL6 and its co-inhibitory proteins, such as NCOR1, with an IC50 value of 6 nM. This compound induces approximately 52% degradation of BCL6 at a concentration of 5 μM over 90 minutes, classifying it as a partial degrader. BCL6-IN-11 is valuable for research applications in studying lymphoma and the role of BCL6 in oncogenesis. -
BCL6 Inhibitor
WK692 is a potent inhibitor of BCL6, specifically targeting the BCL6 BTB/SMRT interaction. This compound demonstrates significant biological activity by effectively inhibiting the growth of diffuse large B-cell lymphoma cells. Furthermore, WK692 has been shown to synergize with EZH2 and PRMT5 inhibitors, making it a valuable tool for research into targeted cancer therapies and the mechanistic understanding of lymphoma progression. -
BCL-6 PROTAC Degrader
BCL6-760 is an orally active BCL-6 PROTAC degrader that selectively targets and degrades BCL-6 with an EC50 of 0.8 nM, without affecting other CRBN substrates. This compound exhibits notable efficacy in orthotopic xenograft mouse models of OCI-LY-1 tumors. BCL6-760 serves as a valuable tool for investigating diffuse large B-cell lymphoma (DLBCL) and for exploring mechanisms related to BCL-6 signaling pathways in cancer research. -
BCL6 PROTAC
BCL6 PROTAC 1 is a selective proteolysis targeting chimera (PROTAC) that targets B-cell lymphoma 6 (BCL6) for degradation. It exhibits potent inhibitory activity on BCL6 cell reporter assays, with an IC50 value of 8.8 µM. This reagent effectively induces degradation of BCL6 in diffuse large B-cell lymphoma (DLBCL) cell lines, making it a valuable tool for tumor-related research applications. -
BCL6 Ligand
BCL6 ligand-8 is a bifunctional linker designed to target the BCL6 protein for degradation via the PROTAC (Proteolysis Targeting Chimeras) mechanism. This compound plays a crucial role in the synthesis of PROTACs, including the effective BCL6-760, known for its anti-tumor properties. BCL6 ligand-8 is primarily utilized in cancer research to explore therapeutic strategies involving protein degradation pathways. -
BCL6 Inhibitor
BCL6-IN-10 is a selective molecular glue inhibitor that targets the BTB domain of BCL6, exhibiting an IC50 of 4 nM. This compound demonstrates significant anti-proliferative activity in diffuse large B-cell lymphoma (DLBCL) cell lines, making it a valuable tool in cancer research. Its unique mechanism of action offers insights into therapeutic strategies for targeting BCL6-associated malignancies. -
BCL6 Ligand
BCL6 ligand-4 is a selective ligand targeting BCL6, a key regulator of oncogenic transcription. This compound is primarily utilized in the synthesis of PROTACs, enabling targeted protein degradation for therapeutic applications in oncology research. BCL6 ligand-4 provides researchers with essential tools to explore BCL6-related pathways and develop innovative cancer treatments. -
BCL6 Inhibitor
SMRT peptide is a BCL6 inhibitor that functions by binding to the BTB domain of BCL6, thereby enhancing its transcriptional repression activity. This compound serves as a valuable tool for studying protein-protein interactions related to BCL6 function in various biological processes. Research applications include investigations into the role of BCL6 in cancer and other diseases where transcriptional regulation is critical. -
BCL6 Ligand
BCL6 ligand-5 is a selective ligand for the BCL6 protein, involved in transcriptional regulation and oncogenesis. This compound serves as a crucial component for the development of PROTAC-based degraders targeting BCL6, such as PROTAC BCL6 Degrader-2. Additionally, BCL6 ligand-5 has applications in tumor research, contributing to the study of cancer biology and therapeutic strategies. -
BCL6
OICR11029 is a selective inhibitor of BCL6, a transcriptional repressor implicated in various cancers. This compound demonstrates significant efficacy in disrupting BCL6 function, making it a valuable tool for investigating its role in tumorigenesis. OICR11029 is particularly useful for research focused on lymphoma and related hematological malignancies. -
Anti-CD19/CD3ε/Albumin Antibody
Faziprumig is a monoclonal antibody that targets CD19, CD3ε, and human serum albumin, exhibiting dissociation constants (Kd) of 0.0738 nM, 7.997 nM, and 0.6 nM, respectively. This reagent effectively activates T cells, leading to their lysis, and demonstrates significant efficacy in targeting and eliminating B-cell malignancies with low CD19 expression. Faziprumig is particularly relevant in the research of non-Hodgkin's lymphoma and various B-cell malignancies. -
CD19/4-1BB Antibody
Englumafusp alfa is a CD19/4-1BB antibody construct designed to enhance immune response by promoting CD19-specific cross-linking of the 4-1BB receptor on T and NK cells. This fusion protein consists of a CD19-specific antibody domain linked to trimerized extracellular domains of human 4-1BB ligand (41BBL). Its key biological activity supports investigations into immuno-oncology applications, particularly in targeting CD19-positive malignancies. Researchers can utilize Englumafusp alfa to study T cell activation and proliferation in the context of cancer therapies. -
Anti-CD19 Monoclonal Antibody
GBR-401 is a humanized anti-CD19 monoclonal antibody that targets CD19 with high affinity for FcγRIIIa. It exhibits potent cytotoxic activity against B-cell malignancies through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and direct cell killing. GBR-401 is effective in depleting malignant B cells and has been shown to prolong survival in various xenograft models using severe combined immunodeficiency (SCID) mice, making it a valuable tool for cancer research and therapeutic development. -
CD2 mAb
BTI-322 is a human IgG1κ monoclonal antibody targeting the CD2 antigen expressed on T cells and natural killer (NK) cells. This reagent demonstrates potent immunosuppressive activity by effectively inhibiting T cell proliferation in response to alloantigens in vitro. BTI-322 is known to recognize a majority of E-rosette-forming peripheral blood lymphocytes and T-cell leukemias, making it suitable for applications in research on renal allograft rejection and steroid-refractory acute graft-versus-host disease. Additionally, BTI-322 serves as a valuable tool for T-cell depletion studies in various immunological contexts. -
Anti-MS4A1/CD20 Monoclonal Antibody
Blidarvetug is a monoclonal antibody that targets MS4A1/CD20, specifically designed for veterinary applications. This reagent is utilized in the investigation of CD20-positive B-cell lymphoma in canine models, facilitating research into the pathophysiology and treatment strategies for this particular type of cancer. Its specificity for CD20 offers valuable insights into B-cell malignancies in veterinary oncology. -
CD20xCD3 Antibody
Imvotamab is a bispecific immunoglobulin M (IgM) antibody targeting CD20 and CD3. It induces T cell activation while preventing excessive stimulation and potential down-regulation of immune responses. This dual-action mechanism makes Imvotamab a valuable tool for research on B-cell malignancies, including multiple myeloma and non-Hodgkin's lymphoma, facilitating studies on immune modulation and therapeutic interventions. -
Anti-CD20 Antibody
BLX-301 is a humanized monoclonal antibody that targets CD20 on B cells. It demonstrates robust anti-tumor activity, making it a valuable tool for research in non-Hodgkin lymphoma and rheumatoid arthritis. This reagent can help elucidate mechanisms of B cell-mediated diseases and contribute to developing targeted therapies. -
Anti-CD79B/CD3E/MS4A1 Antibody
Anafiltamig is a trivalent monoclonal antibody that targets CD79B, CD3E, and MS4A1. This innovative reagent features a humanized IgG1κ anti-CD79B component combined with a bispecific scFv fragment designed to engage CD3E and MS4A1. By simultaneously bridging T and B cells, Anafiltamig activates T cells, leading to the selective elimination of B cell tumors. This compound is particularly useful for research in B cell malignancies, including non-Hodgkin lymphoma. -
CD22 Inhibitor
GSC-718 is a synthetic sialoside and a potent inhibitor of CD22, exhibiting an IC50 value of 0.161 μM for mouse CD22. This compound is known to promote the proliferation of B cells and enhance antibody production. GSC-718 is particularly relevant for research applications involving B-cell lymphoma and autoimmune conditions such as rheumatoid arthritis. -
Anti-CD22 Antibody
RFB4 is an anti-CD22 monoclonal antibody that specifically targets the CD22 antigen, a marker commonly expressed on B-cell malignancies. This antibody can be utilized to generate recombinant immunotoxins by fusing with the pseudomonas exotoxin PE38 through disulfide linkages, such as in the construct RFB4(dsFv)-PE38. RFB4 serves as a vital tool for research focused on cancer, particularly in studies related to lymphoma and other B-cell related diseases. -
CD22 Ligand
CD22 ligand-1 is a potent and selective ligand for CD22, exhibiting a binding affinity (KD) of 0.335 µM for human CD22 and 30.7 µM for myelin-associated glycoprotein (MAG). This compound facilitates the investigation of CD22-mediated signaling pathways and holds potential for advancing research in B-cell related diseases, including autoimmune disorders and lymphomas. Its high specificity for CD22 makes it a valuable tool for understanding the role of this receptor in immunological responses. -
CD276 Monoclonal Antibody
Elfetabart is a humanized monoclonal antibody that specifically targets CD276, exhibiting notable antitumor activity. This antibody belongs to the IgG1κ isotype, making it suitable for various applications in cancer research and therapeutic development. Its interaction with CD276 plays a critical role in modulating immune responses in the tumor microenvironment, thus making it a valuable tool for studying immune evasion and developing immunotherapeutic strategies. -
CD28-B7 Inhibitor
CD28-IN-2 is a selective inhibitor of the CD28-B7 interaction, demonstrating an IC50 of 22.4 μM and a Kd value of 24.1 μM. This compound effectively inhibits CD28-mediated immune activation and prevents T cell costimulation. CD28-IN-2 serves as a valuable tool in research investigating antitumor immunity and various immune-related disorders. -
CD272 Antibody Inhibitor
Radanstobart is a humanized monoclonal antibody that selectively inhibits CD272, a checkpoint protein involved in immune regulation. This antibody exhibits significant antitumor activity, making it valuable for cancer research and immunotherapy studies. It is classified as a human IgG4κ isotype, providing a robust platform for investigating immune responses and potential therapeutic approaches targeting the tumor microenvironment. -
ICOS/CD28 Antagonist
Acazicolcept is an Fc fusion protein that serves as a dual antagonist of the inducible T cell costimulator (ICOS) and CD28. This reagent exhibits significant anti-inflammatory activity, making it valuable for research in autoimmune disorders and T cell modulation. Its unique mechanism of action positions Acazicolcept as a key tool in studying the regulation of immune responses and potential therapeutic interventions. -
B7.1-CD28 Interaction Inhibitor
B7/CD28 Interaction Inhibitor 1 is a selective inhibitor of the B7.1-CD28 interaction, exhibiting an IC50 of 50 nM. This compound disrupts T-cell costimulation, making it a valuable tool for research in immunology and cancer therapy. Its ability to modulate T-cell responses highlights its potential applications in studying immune regulation and developing immunotherapeutic strategies. -
CD28 Inhibitor
DDS5 is a selective CD28 inhibitor with an affinity (kd) of 175.57 µM, effectively disrupting the CD28-CD80 interaction with an IC50 value of 332 µM. This compound is instrumental in researching immune-mediated diseases, including inflammatory bowel disease and rheumatoid arthritis, enabling investigations into immune response modulation and therapeutic strategies. -
Bioactive Peptide
CFP10 (71–85) is a bioactive peptide that stimulates the production of interferon-gamma (IFN-γ) and enhances cytotoxic T lymphocyte (CTL) activity in both CD4+ and CD8+ T cells. It is particularly effective in individuals expressing various MHC class II and class I molecules. This peptide is valuable for research applications focused on immune response modulation and T cell activation. -
EpCAM/CD3 Bispecific Antibody
M701 is a bispecific humanized antibody that targets epithelial cell adhesion molecule (EpCAM) and cluster of differentiation 3 (CD3). By binding to EpCAM on tumor cells and CD3 on T cells, M701 effectively links these two cell populations, facilitating targeted cytotoxicity and enhancing T cell-mediated immune responses. This reagent is particularly valuable for research focused on advanced epithelial solid tumors, aiding in the development of innovative therapies. -
Anti-CD3E Antibody
Ebribafusp alfa is an anti-CD3E IgG4κ chimeric antibody designed to modulate immune responses by targeting the CD3 epsilon subunit of the T cell receptor complex. This compound exhibits potential therapeutic activity in autoimmune diseases and T cell-related conditions by enhancing T cell-mediated immunity. Research applications include investigations into T cell activation and modulation strategies in immunotherapy and transplant biology. -
Anti-CD3E/CD4 Antibody
Amtabafusp alfa is a humanized IgG1 λ1 antibody that targets CD3E and CD4. This recombinant antibody is designed for applications in immunology and cancer research, facilitating the study of T cell activation and tumor microenvironment interactions. It serves as a crucial tool for investigating immune responses and therapeutic strategies in various diseases. -
Anti-FOLH1/PSMA And CD3E Antibody
Olsutamig is a bivalent humanized IgG4κ monoclonal antibody that targets FOLH1/PSMA and CD3E. This reagent effectively binds to the prostate-specific membrane antigen (PSMA) on tumor cells and to CD3E on T cells, leading to significant T cell activation. Olsutamig is primarily employed in research focused on immuno-oncology, particularly for its potential to selectively induce apoptosis in prostate cancer cells through T cell-mediated mechanisms. -
CD38 Inhibitor
CVN14 is a selective and potent inhibitor of CD38, exhibiting inhibitory activity with human and mouse IC50 values of 19 nM and 2.4 nM, respectively. This compound binds uncompetitively to CD38, forming a complex with ADPR and subsequently inhibiting its enzymatic activity. CVN14 is suitable for research applications focused on neurodegenerative diseases, providing insights into the role of CD38 in these conditions. -
CD38 Inhibitor
Luteolinidin chloride is a potent inhibitor of CD38, with a Ki value of 11.4 μM, and demonstrates significant antioxidant activity. This compound has shown to protect cardiac tissue from ischemia/reperfusion injury by preserving the functionality of endothelial nitric oxide synthase (eNOS) and preventing endothelial dysfunction. Additionally, Luteolinidin chloride acts as a competitive inhibitor of tyrosinase, with an IC50 of 3.7 μM, effectively blocking melanin production. This makes it a valuable reagent for research in cardiovascular protection and skin pigmentation studies. -
Anti-CD38 mAb/IFNα2b Fusion Protein
Modakafusp alfa is a humanized anti-CD38 IgG4 monoclonal antibody fused with two attenuated interferon-alpha 2b molecules, targeting CD38-expressing cells. It exhibits direct anti-proliferative activity against multiple myeloma cells in vitro and elicits significant and sustained antitumor responses in xenograft tumor models. Additionally, the combination of Modakafusp alfa with anti-PD-1 antibodies promotes immunomodulation and enhances antitumor efficacy, demonstrating a favorable tolerance profile in murine models. This reagent is valuable for research in multiple myeloma therapy and immune checkpoint modulation. -
CD38 Inhibitor
CD38 Inhibitor 2 is a selective inhibitor of CD38 with an IC50 range of 0.01 to 0.1 μM. This compound demonstrates potent inhibition of CD38 enzymatic activity, making it a valuable tool for studies focused on NAD+ metabolism and immune regulation. Its applications extend to cancer research, immunology, and age-related studies, contributing to a better understanding of the role of CD38 in various biological processes. -
CD38 Inhibitor
Ara-F-NAD+ is an arabino analogue of NAD+ and functions as a potent, reversible, and slow-binding inhibitor of CD38 NADase. This compound effectively modulates NAD+ metabolism, making it a valuable tool for studying the role of CD38 in various biological processes. Ara-F-NAD+ has potential applications in research focused on immune regulation, cellular signaling, and metabolic disorders related to NAD+ homeostasis. -
Anti-CD38 Antibody
Sanritatug is a humanized IgG1κ antibody that specifically targets CD38, a cell surface protein involved in immune regulation and metabolism. This antibody has demonstrated significant potential in modulating immune responses and is being investigated for therapeutic applications in various hematological malignancies and autoimmune diseases. Sanritatug may aid in the exploration of CD38's role in disease pathophysiology and the development of targeted immunotherapies. -
CD38 Inhibitor
6-Alkyne-F-araNAD is an irreversible inhibitor of CD38, a critical enzyme involved in the regulation of cyclic ADP-ribose and NAD metabolism. This compound enhances the efficacy of fluorescent probes, such as SR101-F-araNMN, allowing for improved visualization of intracellular CD38 localization. It serves as a valuable tool in studies related to immune signaling and cellular response mechanisms. -
CD38 Hydrolase Inhibitor
CD38-IN-5 is a selective inhibitor of CD38 hydrolase, exhibiting an IC50 of 4.0 μM, while sparing CD38 cyclase activity. This compound is particularly effective in enhancing natural killer (NK) cell-mediated tumor cytotoxicity and promotes increased levels of NADH+ and IFNγ in activated peripheral blood mononuclear cells (PBMCs). CD38-IN-5 serves as a valuable tool for cancer research, facilitating the investigation of immune modulation and tumor interactions. -
CD38 Inhibitor
(E/Z)-CCR-11 is a selective inhibitor of CD38, exhibiting an IC50 value of 20.8 μM against CD38 cyclase. This compound effectively enhances cellular NAD+ levels and promotes the production of interferon γ. It is valuable for research applications focused on cellular metabolism and immune response modulation. -
HA-CD44 Interaction Inhibitor
HA-CD44 Interaction Inhibitor 2 is an inhibitor that targets the interaction between Hyaluronic acid (HA) and CD44. It exhibits antiproliferative effects on CD44-positive cancer cells, effectively disrupting cancer sphere integrity and decreasing cell viability in a dose-dependent manner. This compound is suitable for applications in tumor research aimed at understanding the role of CD44 in cancer progression. -
HA-CD44 Interaction Inhibitor
HA-CD44 Interaction Inhibitor 1 is a specific inhibitor of the interaction between hyaluronic acid (HA) and CD44. By disrupting this interaction, it demonstrates significant antiproliferative effects on CD44+ cancer cell lines. This compound is valuable for research aimed at understanding cancer progression and potential therapeutic strategies targeting CD44-mediated cellular processes. -
CD47 Inhibitor
Evorpacept is a high-affinity CD47 inhibitor designed to block the CD47-SIRPα immune checkpoint interaction. By binding to CD47, Evorpacept facilitates the inhibition of wild-type SIRPα binding, enhancing immune response against tumors. This reagent is particularly relevant for research applications focused on acute myeloid leukemia and other malignancies where CD47 plays a pivotal role in immune evasion. -
CD47 Fusion Protein
Maplirpacept is a CD47 fusion protein designed to inhibit the CD47 pathway. By binding to CD47, the protein promotes phagocytosis of cancer cells, enhancing the immune response against tumors. This reagent is utilized in research focused on immuno-oncology and the modulation of immune evasion mechanisms in cancer therapy.
